カテゴリ： Allied Market Research, 世界, 医療/バイオ

高効能API（活性医薬品成分）のグローバル市場（2021〜2031）：革新型高効能API、ジェネリック型高効能API

■ 英語タイトル：High Potency APIs Market By Product Type (Innovative High-Potency API, Generic High-Potency API), By Application (Oncology, Hormonal Imbalance, Glaucoma, Others), By Type of Synthesis (Synthetic, Biotech): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23FB249）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23FB249
■ 発行日：2022年10月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：310
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥535,500見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥859,500見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,440,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[高効能API（活性医薬品成分）のグローバル市場（2021〜2031）：革新型高効能API、ジェネリック型高効能API]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートでは、2021年に19,693.65百万ドルであった世界の高効能API（活性医薬品成分）市場規模が、2031年までに41,373.34百万ドルに到達し、2022年から2031年にかけてCAGR（年平均成長率）7.7%で成長すると予測しています。本レポートは、高効能API（活性医薬品成分）の世界市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、製品別（革新型高効能API、ジェネリック型高効能API）分析、用途別（腫瘍、ホルモンバランス、緑内障、その他）分析、合成別（合成、生物由来）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、AbbVie Inc.、Bayer AG、Boehringer Ingelheim International GmbH、Bristol-Myers Squibb Company、Eli Lilly and Company、F. Hoffmann-La Rocheなどの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の高効能API（活性医薬品成分）市場規模：製品別
- 革新型高効能APIの市場規模
- ジェネリック型高効能APIの市場規模
・世界の高効能API（活性医薬品成分）市場規模：用途別
- 腫瘍における市場規模
- ホルモンバランスにおける市場規模
- 緑内障における市場規模
- その他における市場規模
・世界の高効能API（活性医薬品成分）市場規模：合成別
- 合成高効能APIの市場規模
- 生物由来高効能APIの市場規模
・世界の高効能API（活性医薬品成分）市場規模：地域別
- 北米の高効能API（活性医薬品成分）市場規模
- ヨーロッパの高効能API（活性医薬品成分）市場規模
- アジア太平洋の高効能API（活性医薬品成分）市場規模
- 中南米・中東・アフリカの高効能API（活性医薬品成分）市場規模
・企業状況
・企業情報

世界の高効能API（活性医薬品成分）市場は、2021年に196億9,365万ドルと評価され、2022年から2031年までの年平均成長率は7.7%となり、2031年には413億7,334万ドルに達すると予測されています。

高効能API（活性医薬品成分）とは、非常に低用量でも生物学的反応を引き起こす物質です。細胞毒性物質やエストロゲンのような性ホルモンは、性質上選択性が高く、低用量で反応を示すHPAPIの一般的な例です。さらに、フェンタニル、アルプラゾラム、リスペリドン、ブメタニド、ビソプロロールのような低濃度で反応を引き起こす高活性の薬剤が開発され、様々な病気の治療薬として市場に出回っているため、HPAPIの開発を含む原薬開発分野は、製薬業界で最も急速に拡大している分野です。さらに、がん、糖尿病、緑内障などの治療薬として、1,000以上の高活性低分子が開発中です。

National Glaucoma Researchによると、300万人以上のアメリカ人が緑内障を患っており、そのうち270万人は40歳以上で、最も一般的な緑内障である開放隅角緑内障に罹患しています。また、2020年には世界で約8,000万人が緑内障に罹患し、2040年には1億1,100万人以上に増加すると予測されています。このような緑内障患者数の増加は、癌、糖尿病などの他の多遺伝子疾患の世界的な流行とともに、高効能API（活性医薬品成分）市場の成長を促進しています。

さらに、同市場の主要な市場関係者は、インド、中国、中東アジアなどの新興経済圏に投資し、事業を拡大することに注力しています。この地域の人口の増加、製造のための過剰な原材料の普及、政府による資金提供は、この地域の市場の成長を促進する要因です。また、NCBIによると、原発閉塞隅角緑内障（PACG）はヨーロッパやアフリカよりもアジア人に多く、世界全体の症例の80％以上を占めており、予測期間中の高活性API市場における主要市場プレーヤーの投資機会を浮き彫りにしています。

また、世界的な癌の流行により、癌治療薬の需要が増加しています。また、HPAPI製造技術の進歩や製造受託機関（CMO）および開発・製造受託機関（CDMO）の増加が、市場の成長を促進する要因となっています。一方、高効能API（活性医薬品成分）の特許切れやジェネリック医薬品の発売は、製薬企業にとって製品ポートフォリオの充実と事業拡大の好機となると予測されます。
しかし、クロスコンタミネーションのリスクが高く、製造工程に関連する開発コストが高いため、近い将来、市場は大きな制約を受けると予想されます。同市場は資本集約的で、熟練した技術人材が必要。これは、新規参入企業にとって大きな障壁になると予測されます。

高活性API市場は、製品タイプ、用途、合成タイプ、地域によって区分されます。製品タイプ別では、革新的高効力APIとジェネリック高効力APIに分類されます。用途別では、市場はがん、ホルモン不均衡、緑内障、その他に分類されます。合成タイプ別では、合成とバイオテクノロジーに分類されます。バイオはさらに商人とキャプティブに細分化されます。地域別では、北米、欧州、アジア太平洋、LAMEAに市場を分けて分析しています。

本レポートに掲載されている主要企業には、Abbvie Inc.、Bayer AG、Boehringer Ingelheim International GmbH、Bristol-Myers Squibb、Eli Lilly and Company、F. Hoffmann-La Roche Ltd.、Novartis AG、Pfizer Inc.、Sanofi、Teva Pharmaceutical Industries Ltd.などがあります。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの高効能API（活性医薬品成分）市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、市場の実勢機会を特定します。
・主な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
・高効能API（活性医薬品成分）市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域別および世界の高効能API（活性医薬品成分）市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
用途別
がん
ホルモン不均衡
緑内障
その他

合成タイプ別
合成
バイオ

製品タイプ別
革新的高力価原薬
ジェネリック高薬理原薬

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
AbbVie Inc.
Bayer AG
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche
Novartis International AG
Pfizer, Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Patent Landscape
CHAPTER 4: HIGH POTENCY APIS MARKET, BY PRODUCT TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Innovative High-Potency API
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Generic High-Potency API
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: HIGH POTENCY APIS MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Oncology
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Hormonal Imbalance
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Glaucoma
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Others
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
CHAPTER 6: HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS
6.1 Overview
6.1.1 Market size and forecast
6.2 Synthetic
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Biotech
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.3.4 Biotech High Potency APIs Market by Type
6.3.4.1 Merchant Market size and forecast, by region
6.3.4.2 Captive Market size and forecast, by region
CHAPTER 7: HIGH POTENCY APIS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Product Type
7.2.3 North America Market size and forecast, by Application
7.2.4 North America Market size and forecast, by Type of Synthesis
7.2.4.1 North America Biotech High Potency APIs Market by Type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Product Type
7.2.5.1.2 Market size and forecast, by Application
7.2.5.1.3 Market size and forecast, by Type of Synthesis
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Product Type
7.2.5.2.2 Market size and forecast, by Application
7.2.5.2.3 Market size and forecast, by Type of Synthesis
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Product Type
7.2.5.3.2 Market size and forecast, by Application
7.2.5.3.3 Market size and forecast, by Type of Synthesis
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Product Type
7.3.3 Europe Market size and forecast, by Application
7.3.4 Europe Market size and forecast, by Type of Synthesis
7.3.4.1 Europe Biotech High Potency APIs Market by Type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Product Type
7.3.5.1.2 Market size and forecast, by Application
7.3.5.1.3 Market size and forecast, by Type of Synthesis
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Product Type
7.3.5.2.2 Market size and forecast, by Application
7.3.5.2.3 Market size and forecast, by Type of Synthesis
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Product Type
7.3.5.3.2 Market size and forecast, by Application
7.3.5.3.3 Market size and forecast, by Type of Synthesis
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Product Type
7.3.5.4.2 Market size and forecast, by Application
7.3.5.4.3 Market size and forecast, by Type of Synthesis
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Product Type
7.3.5.5.2 Market size and forecast, by Application
7.3.5.5.3 Market size and forecast, by Type of Synthesis
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Product Type
7.3.5.6.2 Market size and forecast, by Application
7.3.5.6.3 Market size and forecast, by Type of Synthesis
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Product Type
7.4.3 Asia-Pacific Market size and forecast, by Application
7.4.4 Asia-Pacific Market size and forecast, by Type of Synthesis
7.4.4.1 Asia-Pacific Biotech High Potency APIs Market by Type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Product Type
7.4.5.1.2 Market size and forecast, by Application
7.4.5.1.3 Market size and forecast, by Type of Synthesis
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Product Type
7.4.5.2.2 Market size and forecast, by Application
7.4.5.2.3 Market size and forecast, by Type of Synthesis
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Product Type
7.4.5.3.2 Market size and forecast, by Application
7.4.5.3.3 Market size and forecast, by Type of Synthesis
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Product Type
7.4.5.4.2 Market size and forecast, by Application
7.4.5.4.3 Market size and forecast, by Type of Synthesis
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Product Type
7.4.5.5.2 Market size and forecast, by Application
7.4.5.5.3 Market size and forecast, by Type of Synthesis
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Product Type
7.4.5.6.2 Market size and forecast, by Application
7.4.5.6.3 Market size and forecast, by Type of Synthesis
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Product Type
7.5.3 LAMEA Market size and forecast, by Application
7.5.4 LAMEA Market size and forecast, by Type of Synthesis
7.5.4.1 LAMEA Biotech High Potency APIs Market by Type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Product Type
7.5.5.1.2 Market size and forecast, by Application
7.5.5.1.3 Market size and forecast, by Type of Synthesis
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Product Type
7.5.5.2.2 Market size and forecast, by Application
7.5.5.2.3 Market size and forecast, by Type of Synthesis
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Product Type
7.5.5.3.2 Market size and forecast, by Application
7.5.5.3.3 Market size and forecast, by Type of Synthesis
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Product Type
7.5.5.4.2 Market size and forecast, by Application
7.5.5.4.3 Market size and forecast, by Type of Synthesis
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 AbbVie Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Bayer AG
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Boehringer Ingelheim International GmbH
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Bristol-Myers Squibb Company
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Eli Lilly and Company
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 F. Hoffmann-La Roche
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Novartis International AG
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Pfizer, Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Sanofi
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Teva Pharmaceutical Industries Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 2. HIGH POTENCY APIS MARKET, FOR INNOVATIVE HIGH-POTENCY API, BY REGION, 2021-2031 ($MILLION)
TABLE 3. HIGH POTENCY APIS MARKET FOR INNOVATIVE HIGH-POTENCY API, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. HIGH POTENCY APIS MARKET, FOR GENERIC HIGH-POTENCY API, BY REGION, 2021-2031 ($MILLION)
TABLE 5. HIGH POTENCY APIS MARKET FOR GENERIC HIGH-POTENCY API, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. GLOBAL HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 7. HIGH POTENCY APIS MARKET, FOR ONCOLOGY, BY REGION, 2021-2031 ($MILLION)
TABLE 8. HIGH POTENCY APIS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 9. HIGH POTENCY APIS MARKET, FOR HORMONAL IMBALANCE, BY REGION, 2021-2031 ($MILLION)
TABLE 10. HIGH POTENCY APIS MARKET FOR HORMONAL IMBALANCE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. HIGH POTENCY APIS MARKET, FOR GLAUCOMA, BY REGION, 2021-2031 ($MILLION)
TABLE 12. HIGH POTENCY APIS MARKET FOR GLAUCOMA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. HIGH POTENCY APIS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 14. HIGH POTENCY APIS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. GLOBAL HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 16. HIGH POTENCY APIS MARKET, FOR SYNTHETIC, BY REGION, 2021-2031 ($MILLION)
TABLE 17. HIGH POTENCY APIS MARKET FOR SYNTHETIC, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. HIGH POTENCY APIS MARKET, FOR BIOTECH, BY REGION, 2021-2031 ($MILLION)
TABLE 19. HIGH POTENCY APIS MARKET FOR BIOTECH, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 20. GLOBAL BIOTECH HIGH POTENCY APIS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 21. HIGH POTENCY APIS MARKET, FOR MERCHANT, BY REGION, 2021-2031 ($MILLION)
TABLE 22. HIGH POTENCY APIS MARKET, FOR CAPTIVE, BY REGION, 2021-2031 ($MILLION)
TABLE 23. HIGH POTENCY APIS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 24. NORTH AMERICA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 25. NORTH AMERICA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 26. NORTH AMERICA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA BIOTECH HIGH POTENCY APIS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA HIGH POTENCY APIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 29. U.S. HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 30. U.S. HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 31. U.S. HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 32. CANADA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 33. CANADA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 34. CANADA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 35. MEXICO HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 36. MEXICO HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 37. MEXICO HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 38. EUROPE HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 39. EUROPE HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 40. EUROPE HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 41. EUROPE BIOTECH HIGH POTENCY APIS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 42. EUROPE HIGH POTENCY APIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 43. GERMANY HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 44. GERMANY HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 45. GERMANY HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 46. FRANCE HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 47. FRANCE HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 48. FRANCE HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 49. UK HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 50. UK HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 51. UK HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 52. ITALY HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 53. ITALY HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 54. ITALY HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 55. SPAIN HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 56. SPAIN HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 57. SPAIN HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 58. REST OF EUROPE HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 59. REST OF EUROPE HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 60. REST OF EUROPE HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 61. ASIA-PACIFIC HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 62. ASIA-PACIFIC HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 63. ASIA-PACIFIC HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 64. ASIA-PACIFIC BIOTECH HIGH POTENCY APIS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC HIGH POTENCY APIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 66. JAPAN HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 67. JAPAN HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 68. JAPAN HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 69. CHINA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 70. CHINA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 71. CHINA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 72. AUSTRALIA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 73. AUSTRALIA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 74. AUSTRALIA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 75. INDIA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 76. INDIA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 77. INDIA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 78. SOUTH KOREA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 79. SOUTH KOREA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 80. SOUTH KOREA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 81. REST OF ASIA-PACIFIC HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 82. REST OF ASIA-PACIFIC HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 83. REST OF ASIA-PACIFIC HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 84. LAMEA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 85. LAMEA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 86. LAMEA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 87. LAMEA BIOTECH HIGH POTENCY APIS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 88. LAMEA HIGH POTENCY APIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 89. BRAZIL HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 90. BRAZIL HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 91. BRAZIL HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 92. SAUDI ARABIA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 93. SAUDI ARABIA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 94. SAUDI ARABIA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 95. SOUTH AFRICA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 96. SOUTH AFRICA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 97. SOUTH AFRICA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 98. REST OF LAMEA HIGH POTENCY APIS MARKET, BY PRODUCT TYPE, 2021-2031 ($MILLION)
TABLE 99. REST OF LAMEA HIGH POTENCY APIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 100. REST OF LAMEA HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS, 2021-2031 ($MILLION)
TABLE 101.ABBVIE INC.: COMPANY SNAPSHOT
TABLE 102.ABBVIE INC.: OPERATING SEGMENTS
TABLE 103.ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 104.ABBVIE INC.: NET SALES,
TABLE 105.ABBVIE INC.: KEY STRATERGIES
TABLE 106.BAYER AG: COMPANY SNAPSHOT
TABLE 107.BAYER AG: OPERATING SEGMENTS
TABLE 108.BAYER AG: PRODUCT PORTFOLIO
TABLE 109.BAYER AG: NET SALES,
TABLE 110.BAYER AG: KEY STRATERGIES
TABLE 111.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
TABLE 112.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OPERATING SEGMENTS
TABLE 113.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
TABLE 114.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES,
TABLE 115.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY STRATERGIES
TABLE 116.BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 117.BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
TABLE 118.BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 119.BRISTOL-MYERS SQUIBB COMPANY: NET SALES,
TABLE 120.BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
TABLE 121.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 122.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 123.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 124.ELI LILLY AND COMPANY: NET SALES,
TABLE 125.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 126.F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT
TABLE 127.F. HOFFMANN-LA ROCHE: OPERATING SEGMENTS
TABLE 128.F. HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO
TABLE 129.F. HOFFMANN-LA ROCHE: NET SALES,
TABLE 130.F. HOFFMANN-LA ROCHE: KEY STRATERGIES
TABLE 131.NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
TABLE 132.NOVARTIS INTERNATIONAL AG: OPERATING SEGMENTS
TABLE 133.NOVARTIS INTERNATIONAL AG: PRODUCT PORTFOLIO
TABLE 134.NOVARTIS INTERNATIONAL AG: NET SALES,
TABLE 135.NOVARTIS INTERNATIONAL AG: KEY STRATERGIES
TABLE 136.PFIZER, INC.: COMPANY SNAPSHOT
TABLE 137.PFIZER, INC.: OPERATING SEGMENTS
TABLE 138.PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 139.PFIZER, INC.: NET SALES,
TABLE 140.PFIZER, INC.: KEY STRATERGIES
TABLE 141.SANOFI: COMPANY SNAPSHOT
TABLE 142.SANOFI: OPERATING SEGMENTS
TABLE 143.SANOFI: PRODUCT PORTFOLIO
TABLE 144.SANOFI: NET SALES,
TABLE 145.SANOFI: KEY STRATERGIES
TABLE 146.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 147.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 148.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 149.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
TABLE 150.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 治療薬物モニタリング（TDM）のグローバル市場（2021-2031）：消耗品、装置
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23FB249 )"高効能API（活性医薬品成分）のグローバル市場（2021〜2031）：革新型高効能API、ジェネリック型高効能API" (英文：High Potency APIs Market By Product Type (Innovative High-Potency API, Generic High-Potency API), By Application (Oncology, Hormonal Imbalance, Glaucoma, Others), By Type of Synthesis (Synthetic, Biotech): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。